Newron Pharmaceuticals S.p.A.

LSE:0QOI Stock Report

Market Cap: CHF 165.2m

Newron Pharmaceuticals Past Earnings Performance

Past criteria checks 0/6

Newron Pharmaceuticals has been growing earnings at an average annual rate of 4.7%, while the Pharmaceuticals industry saw earnings declining at 5.2% annually. Revenues have been growing at an average rate of 7.7% per year.

Key information

4.7%

Earnings growth rate

4.9%

EPS growth rate

Pharmaceuticals Industry Growth14.1%
Revenue growth rate7.7%
Return on equityn/a
Net Margin-270.2%
Next Earnings Update01 Apr 2025

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Newron Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

LSE:0QOI Revenue, expenses and earnings (EUR Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 247-19814
31 Mar 248-18814
31 Dec 239-16813
30 Sep 239-16813
30 Jun 239-16812
31 Mar 237-17712
31 Dec 226-17712
30 Sep 226-16711
30 Jun 226-14710
31 Mar 226-15710
31 Dec 216-15711
30 Sep 216-17812
30 Jun 215-20814
31 Mar 215-20814
31 Dec 205-21815
30 Sep 206-19915
30 Jun 207-17915
31 Mar 207-181016
31 Dec 197-201017
30 Sep 196-211116
30 Jun 194-211115
31 Mar 194-181012
31 Dec 184-15910
30 Sep 184-1599
30 Jun 184-1499
31 Mar 189-1098
31 Dec 1713-598
30 Sep 1714-5108
30 Jun 1715-5108
31 Mar 1711-101010
31 Dec 167-151012
30 Sep 166-201013
30 Jun 164-25915
31 Mar 163-24913
31 Dec 152-23911
30 Sep 152-1889
30 Jun 152-1286
31 Mar 152-1175
31 Dec 142-1074
30 Sep 142-1074
30 Jun 143-974
31 Mar 143-873
31 Dec 134-772

Quality Earnings: 0QOI is currently unprofitable.

Growing Profit Margin: 0QOI is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 0QOI is unprofitable, but has reduced losses over the past 5 years at a rate of 4.7% per year.

Accelerating Growth: Unable to compare 0QOI's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 0QOI is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (9.5%).


Return on Equity

High ROE: 0QOI's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/24 07:19
End of Day Share Price 2024/12/20 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Newron Pharmaceuticals S.p.A. is covered by 14 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Leonildo DelgadoBaader Helvea Equity Research
Thomas MeyerBaader Helvea Equity Research
Volker BosseBaader Helvea Equity Research